Speaker Profile

Managing Partner, 5AM Ventures
Biography

Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital where he was involved with such companies as Cubist, PTC Therapeutics, Symyx and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, Flexion (NASDAQ: FLXN), Ilypsa (acquired by Amgen), Panomics (acquired by Affymetrix), Precision NanoSystems, and Synosia (acquired by Biotie). Mr. Schwab also serves on the Board of Trustees of the California Academy of Sciences. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team. Mr. Schwab is based in the Menlo Park, CA office.

Session Abstract – PMWC 2017 Silicon Valley

Session Synopsis: Personalized Medicine investment is still in its adolescence in both therapeutics and diagnostics. There have been a few huge wins but also unexpected disappointments. The panel will discuss where PM goes next and the hallmarks of an early success or failure.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!